middle.news
How Will Nyrada’s Xolatryp® Perform in Upcoming Phase IIa Trial?
2:22pm on Wednesday 18th of February, 2026 AEDT
•
Healthcare
Read Story
How Will Nyrada’s Xolatryp® Perform in Upcoming Phase IIa Trial?
2:22pm on Wednesday 18th of February, 2026 AEDT
Key Points
Half-year loss increased to $3.19 million from $2.46 million
Cash reserves strengthened to $7.12 million
Xolatryp® cleared Phase I with strong safety, entering Phase IIa for myocardial ischemia reperfusion injury
New Managing Director appointed; Non-Executive Director resigned
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nyrada (ASX:NYR)
OPEN ARTICLE